Semnur Pharmaceuticals, Inc.
SMNR
$9.00
-$10.00-52.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 497.00K | 478.00K | 802.50K | 802.50K | 801.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 999.00K | 665.00K | 1.04M | 1.04M | 1.11M |
| Operating Income | -999.00K | -665.00K | -1.04M | -1.04M | -1.11M |
| Income Before Tax | -999.00K | -665.00K | -1.04M | -1.04M | -1.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -999.00K | -665.00K | -1.04M | -1.04M | -1.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -999.00K | -665.00K | -1.04M | -1.04M | -1.11M |
| EBIT | -999.00K | -665.00K | -1.04M | -1.04M | -1.11M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 160.00M | 160.00M | 160.00M | 160.00M | 160.00M |
| Average Diluted Shares Outstanding | 160.00M | 160.00M | 160.00M | 160.00M | 160.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |